Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon May 12, 2024 1:37pm
95 Views
Post# 36035948

RE:RE:RE:RE:How does Accelerated Approval work

RE:RE:RE:RE:How does Accelerated Approval work May 07, 2024 - “The facts clearly show the accelerated approval pathway is providing new hope and meaningful new treatments for patients to fight their disease, and why we shouldn’t be misled by biased studies that distort reality,” concludes BIO.

https://www.bio.org/gooddaybio-archive/setting-record-straight-accelerated-approval

May 08, 2024 - "Using a biomarker to obtain accelerated approval is key to get an initial approval for therapies that address devastating diseases, rather than wait for a clinical endpoint to show efficacy in a longer trial" according to the FDA’s Peter Marks, M.D., Ph.D.

“The wherewithal to do a three-year study or a four-year study without having a revenue stream, it's just beyond many companies that are startups. So having the accelerated approval process is a way to get there,” Marks said during a recent American Society of Gene and Cell Therapy (ASGCT) meeting. 


As long as a biomarker is scientifically validated, Marks said, more products can get to the patients that need them.

https://www.fiercebiotech.com/biotech/preventing-3-billion-visits-fda-year-cbers-peter-marks

<< Previous
Bullboard Posts
Next >>